Recombinant lactic acid bacteria as mucosal biotherapeutic agents - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Trends in Biotechnology Année : 2011

Recombinant lactic acid bacteria as mucosal biotherapeutic agents

Résumé

The safety status of lactic acid bacteria (LAB) and their capacity to survive the passage through the gastrointestinal tract (GI tract) have rendered them excellent candidates for the production of therapeutic proteins and their delivery in situ to the GI tract. During the past two decades, major health benefits of mucosally administered recombinant LAB have been successfully demonstrated, predominantly using animal models. However, the field has recently moved into the era of human clinical trials. In this review, we provide a timely update on the recent important advances made in this field, and outline the potential of recombinant LAB as therapeutic tools for their safe and efficient use in human health.

Dates et versions

hal-03300733 , version 1 (27-07-2021)

Identifiants

Citer

Catherine Daniel, Yvonne Roussel, Michiel Kleerebezem, Bruno Pot. Recombinant lactic acid bacteria as mucosal biotherapeutic agents. Trends in Biotechnology, 2011, 29 (10), pp.499-508. ⟨10.1016/j.tibtech.2011.05.002⟩. ⟨hal-03300733⟩
5 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More